Oncology Medical News about untreated multiple myeloma;Thalidomide plus Dexamethasone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a Southwest Oncology Group trial (S0204)
Journal of Clinical Oncology, 06/25/09

Hussein MA et al. - In a study to assess improved survival results reported for the predecessor, phase III trial S9321 by 50%, it was shown that both overall survival (OS) and event-free survival (EFS) were significantly improved with S0204 compared with S9321 when 121 and 363 pts, respectively, were matched on International Staging System (ISS) stage and lactate dehydrogenase (LDH).

Methods

Newly diagnosed pts with multiple myeloma (MM) were eligible for S0204 with thalidomide-dexamethasone (THAL-DEX) induction, tandem melphalan-based tandem transplantation, and THAL-prednisone maintenance.

Results

Of 143 eligible pts, 142 started induction, 73% completed first transplantation, 58% completed second transplantation, and 56% started maintenance.
The quantity of stem cells required for 2 transplantations was reached in 88% of 111 pts undergoing collection, 74% of whom completed both transplantations.
Partial response, very good partial remission, and complete response were documented after 12 mos of maintenance therapy in 87%, 72%, and 22% of pts, respectively.
During a median follow-up time of 37 mos, 4-yr estimates of EFS and OS were 50% and 64%, respectively.
Survival outcomes were superior for ISS stage 1 disease, when LDH levels were normal and a second transplantation was applied in a timely fashion.

<< Previous
Pentoxifylline and vitamin E treatment for prevention of...

Next >>
Safety, pharmacokinetics, and antitumor activity of AMG 386, a...

VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III Vista study
Journal of Clinical Oncology, 10/29/09 Relevance Score: 80%

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09 Relevance Score: 79%

Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09 Relevance Score: 69%

Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09 Relevance Score: 69%

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09 Relevance Score: 69%